OpenAI put GPT-Rosalind into research preview for qualified life-science teams, pairing a domain model with a Codex plugin that connects to more than 50 tools and data sources. The strongest signal is not the branding: OpenAI says best-of-ten submissions ranked above the 95th percentile of human experts on one Dyno Therapeutics RNA prediction task.
OpenAI is moving model specialization into scientific work rather than generic chat. GPT-Rosalind is framed for protein reasoning, chemical reasoning, genomics, biochemistry and tool use, with access starting as a research preview for qualified customers including Amgen and Moderna.
NVIDIA says its latest healthcare and life sciences AI survey shows the market moving beyond experimentation and toward measurable ROI. The company reports that 70% of surveyed organizations are already using AI and 69% are using generative AI and large language models.
NVIDIA says Lilly has brought LillyPod online, a pharma-owned AI factory built with 1,016 Blackwell Ultra GPUs and more than 9,000 petaflops of AI performance. The platform is intended to accelerate model training and simulation across genomics, small molecules, and clinical-development workflows.
Anthropic announced expanded Claude offerings for healthcare and life sciences, naming Intermountain Health, EVERSANA, and PathAI as key partners. The solutions are available via AWS Marketplace and the Anthropic API, with focus areas including clinical trial matching and patient-facing operations.
Anthropic announced on February 2, 2026 that it is partnering with the Allen Institute and Howard Hughes Medical Institute (HHMI) on AI-enabled life-science workflows. The stated goal is to reduce analysis bottlenecks and improve transparent, interpretable scientific reasoning.